Delisting riskPopularity #3,841
Silexion Therapeutics (SLXN)
Develops RNA-targeting treatment candidates for KRAS-mutated pancreatic cancer.
$0.4701
vs last close−0.07 (−13.60%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
estimated · in 50 days
EPS estimate
−$9.10
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$115.50−$38.98−$43.20−$28.80−$23.85−$8.50−$5.17Pending
Estimate−$147.00−$33.00−$31.50−$34.00−$1.17−$12.90−$21.20−$9.10
Surprise+21.4%−18.1%−37.1%+15.3%−1,938.5%+34.1%+75.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$7.10 | — | — |
| Nov 2026 | −$9.10 | — | — |
| Aug 2026 | −$21.20 | −$5.17 | +75.6% |
| May 2026 | −$12.90 | −$8.50 | +34.1% |
| Mar 2026 | −$1.17 | −$23.85 | −1,938.5% |
| Nov 2025 | −$34.00 | −$28.80 | +15.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$7.10 | — | — | $0 | — | — | — |
| Nov 11, 2026 | −$9.10 | — | — | $0 | — | — | — |
| Aug 14, 2026 | −$21.20 | −$5.17 | +75.6% | — | — | — | −8.7% |
| May 12, 2026 | −$12.90 | −$8.50 | +34.1% | — | — | — | +14.2% |
| Mar 17, 2026 | −$1.17 | −$23.85 | −1,938.5% | — | — | — | −0.6% |
| Nov 12, 2025 | −$34.00 | −$28.80 | +15.3% | — | — | — | +3.6% |
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 18, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 15, 2024 |